On 12/4/24, Cidara Therapeutics Inc (NASDAQ: CDTX) stock enjoyed a major increase of 12.6%, closing at $19.95. Moreover, this advance was accompanied by exceptionally high trading volume at 244% of normal. The stock has been weak relative to the market over the last nine months but has risen 6.7% during the last week.
Current PriceTarget Research Rating
Cidara Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment